Risk for CRC Reduced With GLP-1RAs for Drug-Naive Patients With T2D
GLP-1 receptor agonists linked to reduced risk for CRC compared with other antidiabetics, including insulin and metformin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.